Skip to main
RMTI

Rockwell Medical (RMTI) Stock Forecast & Price Target

Rockwell Medical (RMTI) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rockwell Medical is expected to generate a gradual improvement in gross margins and operating efficiency over the coming quarters, with financial results for the second quarter of 2026 showing increases in top-line revenue. The company has reached a balance sheet of $24.8M in cash, cash equivalents, and marketable securities, a modest increase from previous quarters. While a reverse stock split became effective on July 1, 2026, adjusting the price target to $20 from $2, the company is anticipated to bring itself into compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ exchange.

Bears say

Rockwell Medical is facing several challenges that could significantly impact its financial performance and stock performance. The company has a negative outlook due to its current valuation, which is based on a discounted cash flow assessment of only $90M. The risks associated with Rockwell Medical include a failure to achieve market traction, partnership risks, commercial setbacks, inability to control expenses, and potential equity dilution. The recent compliance with Nasdaq listing requirements is a positive development, but our Buy rating and price target of $20 per share remains unchanged.

Rockwell Medical (RMTI) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rockwell Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rockwell Medical (RMTI) Forecast

Analysts have given Rockwell Medical (RMTI) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Rockwell Medical (RMTI) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rockwell Medical (RMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.